Follicular lymphoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Follicular lymphoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ Thu, 30 Apr 2026 13:07:57 +0000 https://clinicaltrials.eu/trial/study-of-bgb-16673-in-combination-with-drug-therapy-for-patients-with-relapsed-or-refractory-b-cell-malignancies/ This clinical trial is studying treatments for B-cell malignancies that have returned or not responded to previous treatments. The study will test different combinations of medications, including BGB-16673, zanubrutinib, sonrotoclax, mosunetuzumab, obinutuzumab, and glofitamab. The purpose is to find safe and effective treatment combinations for patients whose cancer has come back or did not respond to earlier treatments.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

]]> Study on the Effectiveness and Safety of Golcadomide and Rituximab for Patients with Newly Diagnosed Advanced Follicular Lymphoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-golcadomide-and-rituximab-for-patients-with-newly-diagnosed-advanced-follicular-lymphoma/ Wed, 29 Apr 2026 14:59:05 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-golcadomide-and-rituximab-for-patients-with-newly-diagnosed-advanced-follicular-lymphoma/ This clinical trial is focused on studying a type of cancer called Follicular Lymphoma, which is a form of non-Hodgkin lymphoma. The study involves patients who have been newly diagnosed with advanced stages of this disease. The treatment being tested combines two medications: Golcadomide and Rituximab. Golcadomide, also known by its code name CC-99282, is taken orally in capsule form, while Rituximab is administered as an infusion, meaning it is given directly into the bloodstream through a vein.

The purpose of the study is to evaluate the effectiveness and safety of this combination treatment. The main goal is to see if the treatment can achieve a Complete Metabolic Response (CMR), which means that after treatment, tests show no signs of cancer in the body. The study will also monitor for any side effects or adverse events, which are any negative impacts on health that occur during the treatment. These include any new side effects that appear after starting the treatment, known as Treatment-Emergent Adverse Events (TEAEs).

Participants in the study will receive the treatment over a period of time, and their response will be evaluated at different stages, such as 6 months and 12 months after starting the treatment. The study will also assess the overall response rate (ORR), which is the percentage of participants whose cancer shrinks or disappears, as well as progression-free survival (PFS) and overall survival (OS). PFS is the time from the start of treatment until the disease worsens or the patient passes away, while OS is the time from the start of treatment until the patient passes away. The study aims to provide valuable information on the potential benefits and risks of using Golcadomide and Rituximab together for treating advanced stage Follicular Lymphoma.

]]>